fashion -WSS

fashion

author：hotspot 2025-09-06 03:33:44 - browse：26

Stock exchange — Drew Angerer/Getty Images

Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two small studies, leading shares to surge in pre-market trading.

In a 12-week Phase 2a study, the daily pill in a capsule formulation led to 6.2% placebo-adjusted weight loss. In a separate 12-week pharmacokinetics study, the company tested a new tablet formulation of the drug, called GSBR-1290, and it led to placebo-adjusted weight loss of up to 6.9%.

Though it’s difficult to compare across different studies, the results appear to approach the levels of weight loss seen at 12 weeks in a separate Phase 2 study of Eli Lilly’s GLP-1 pill called orforglipron. That entire study lasted 36 weeks, but at 12 weeks, participants had about 6%-7% placebo-adjusted weight loss.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： FDA reorg will put new emphasis on investigations, sources say

WSS

Focused ultrasound for uterine fibroids: an uphill battle

White House drug czar issues call for 'recovery

Focused ultrasound for uterine fibroids: an uphill battle

Lab trade group sues FDA to halt regulation of lab

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

NIH chief: government has fallen behind pharma on clinical trials

focus

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Dobbs anniversary: the lost opportunity of abortion as health care

AI used to predict Covid

Tori Bowie and the unacceptable rates of Black maternal death

What health policies could hitch a ride on a spending bill?

Drug repurposing or repositioning? The language matters

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

The cancer drug shortage isn’t new — and neither are the solutions

Addiction doctors spar with methadone clinics over legislation

After affirmative action ruling, medical educators look to 'holistic review'

Study suggests Covid rebound is far more common with Paxlovid than without

leisure time

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Publishing genetic code of viruses could cause disaster

Publishing genetic code of viruses could cause disaster

After decades in use, heart stents finally beat placebo

Experimental asthma app from Apple and Anthem shows promise

NIH chief: government has fallen behind pharma on clinical trials

hotspot

entertainment

explore

hotspot